MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Clebopride-induced Rabbit Syndrome: A Case Report.

    IA. Ortiz-Marroquin, E. Valdez-Rodriguez, V. Rodriguez-Martinez, D. Martinez-Ramirez (Monterrey, Mexico)

    Objective: This report aims to present a case of rabbit syndrome attributed to clebopride and to highlight the importance of considering nonneuroleptic drugs as a…
  • 2023 International Congress

    Trends in the evaluation and management of constipation in patients with Parkinson disease

    L. Deuel, W. Wright, E. Houston (Burlington, USA)

    Objective: Explore common evaluation and management strategies for constipation in patients with Parkinson disease (PD) at a tertiary center. Background: PD is diagnosed based on…
  • 2023 International Congress

    The diagnosis value of dopaminergic responsiveness of Parkinson’s disease: a systematic review and meta-analysis

    WY. Kou, HH. Cai, FT. Feng (beijiing, China)

    Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…
  • 2023 International Congress

    Case report on heterozygous OPA3 gene mutation causing ataxia

    J. Ng, T. Stiep (San Francisco, USA)

    Objective: To describe a case of adult-onset ataxia with a heterozygous p.Lys10Asn OPA3 mutation. Background: Mutations in the OPA3 gene, which encodes a mitochondrial membrane…
  • 2023 International Congress

    Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders

    KA. Woo, HJ. Chang, JY. Joo, JH. Shin, SY. Kim, SM. Lee, BR. Jin, HY. Jeon, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

    Objective: To investigate the differences in the pattern of nigrostriatal and pontine monoaminergic degeneration patients with de novo Parkinson's disease (PD), stratified by the presence…
  • 2023 International Congress

    The prevalence and characteristics of REM sleep behavior disorder in progressive supranuclear palsy patients.

    APH. Phoumindr, JSR. Srignean, RBH. Bhidayasiri (Bangkok, Thailand)

    Objective: To describe the prevalence and characteristics of RBD in patients diagnosed with PSP and to demonstrate the association with each PSP subtype. Background: Rapid…
  • 2023 International Congress

    Baseline fluid biomarkers in a phase 2 clinical trial in Parkinson’s Disease

    T. Kustermann, G. Pagano, H. Svoboda, T. Nikolcheva, K. Taylor (Basel, Switzerland)

    Objective: To evaluate baseline CSF and blood-based biomarkers of pathology in early-stage Parkinson’s Disease (PD) participants in the phase 2 clinical trial PASADENA. Background: Observational…
  • 2023 International Congress

    Detection of Levodopa induced Dyskinesia based on spectral features from subthalamic-LFP and sensorimotor-ECoG

    J. Habets, R. Lofredi, J. Busch, V. Mathiopoulou, J. Roediger, R. Koehler, J. Vanhoecke, P. Krause, K. Faust, GH. Schneider, WJ. Neumann, A. Kühn (Berlin, Germany)

    Objective: To detect the presence of Levodopa induced Dyskinesia (LID) in Parkinson’s disease (PD) patients based on spectral characteristics from invasive cortico-subthalamic recordings using machine…
  • 2023 International Congress

    Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis

    F. Al Hajraf, S. Manohar, M. Hu (Oxford, United Kingdom)

    Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…
  • 2023 International Congress

    Dopamine dysfunction in nigro-striatal pathway—multi-axial pathology in SCA 12

    P. Basu, J. Ganguly, S. Pandey, S. Mukherjee, N. Singh, S. Choudhury, H. Kumar (Kolkata, India)

    Objective: To assert pathophysiology in spinocerebellar ataxia type 12 (SCA12) extends way beyond cerebellar or spinal pathology. To further sensitise scientific community about consistent nigro-striatal…
  • « Previous Page
  • 1
  • …
  • 180
  • 181
  • 182
  • 183
  • 184
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley